Please Wait
Applying Filters...
menu
    • menu
    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    Menu

    Bezisterim

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    BioVie To Present Phase 2 Study Design Of Bezisterim For Long COVID
    BioVie To Present Phase 2 Study Design Of Bezisterim For Long COVID

    20 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/20/2984379/0/en/BioVie-to-Present-Design-of-Planned-Phase-2-Study-of-Bezisterim-for-the-Treatment-of-Long-COVID-at-the-Demystifying-Long-COVID-International-Conference.html

    GLOBENEWSWIRE
    20 Nov 2024
    Share Share
    BioVie Secures Approvals For $12.6M Grant For COVID Trial
    BioVie Secures Approvals For $12.6M Grant For COVID Trial

    16 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/16/2946557/0/en/BioVie-Secures-All-Scientific-Approvals-Needed-to-Receive-Additional-12-6-Million-of-Grant-Funding-to-Launch-Planned-Phase-2-Trial-to-Evaluate-Bezisterim-in-Long-COVID.html

    GLOBENEWSWIRE
    16 Sep 2024
    Share Share
    BioVie Announces FDA Approval for Phase 2 Long COVID Trial of Bezisterim
    BioVie Announces FDA Approval for Phase 2 Long COVID Trial of Bezisterim

    03 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/03/2939596/0/en/BioVie-Announces-FDA-Authorization-of-Investigational-New-Drug-Application-for-Phase-2-Trial-to-Evaluate-Bezisterim-in-Long-COVID.html

    GLOBENEWSWIRE
    03 Sep 2024
    Share Share
    BioVie Presents Bezisterim Data At Aging Research And Drug Discovery Meeting
    BioVie Presents Bezisterim Data At Aging Research And Drug Discovery Meeting

    27 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/27/2936255/0/en/BioVie-Announces-Clinical-Data-Showing-Epigenetic-Basis-for-How-Bezisterim-May-Modulate-Inflammation-and-the-Biological-Aging-Process-at-the-11th-Aging-Research-and-Drug-Discovery-.html

    GLOBENEWSWIRE
    27 Aug 2024
    Share Share
    BioVie To Present Bezisterim Data At Aging Research Conference
    BioVie To Present Bezisterim Data At Aging Research Conference

    13 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/13/2929149/0/en/BioVie-to-Present-Overview-of-Bezisterim-Clinical-Data-on-Longevity-at-11th-Aging-Research-and-Drug-Discovery-Meeting.html

    GLOBENEWSWIRE
    13 Aug 2024
    Share Share
    Privia Health Reports Second Quarter 2024 Financial Results
    Privia Health Reports Second Quarter 2024 Financial Results

    08 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/08/2926681/0/en/Privia-Health-Reports-Second-Quarter-2024-Financial-Results.html

    GLOBENEWSWIRE
    08 Aug 2024
    Share Share